Matt Fisher
Member of the Tumour Microcirculation Group
Oncology & Metabolism
University of Sheffield
United Kingdom
Biography
After completing my degree in 2006 I joined the University of Sheffield in 2007 as a research technician. I am a member of the Tumour Microcirculation Group (TMG) headed by Prof. Gillian Tozer.
Research Interest
The TMG study the blood vessels that supply tumours with oxygen and nutrients and their role in cancer therapy. Tumours require a blood supply to grow and the blood vessels provide a route for the spread of tumour cells to other sites in the body. Therefore, targeting treatment to the blood vessels rather than the tumour cells is a potential means of killing tumours. Much of the research involves using vascular disrupting agents (VDAs) e.g. CA4P, and the susceptibility of tumour vessels to vascular shutdown.
Publications
-
Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, Di Serio C, Naldini L, De Palma M, Tozer GM, Lewis CE. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. The Journal of clinical investigation. 2011 May 2;121(5):1969.
-
Akerman S, Reyes-Aldasoro CC, Fisher M, Pettyjohn KL, Björndahl MA, Evans H, Tozer GM. Microflow of fluorescently labelled red blood cells in tumours expressing single isoforms of VEGF and their response to vascular targeting agents. Medical engineering & physics. 2011 Sep 30;33(7):805-9.
-
Jane Lunt S, Akerman S, Hill SA, Fisher M, Wright VJ, Reyesâ€Aldasoro CC, Tozer GM, Kanthou C. Vascular effects dominate solid tumor response to treatment with combretastatin Aâ€4â€phosphate. International journal of cancer. 2011 Oct 15;129(8):1979-89.
